华商新闻

20种药品被重点监控“神药”清退加速

The list of 172 pharmaceutical companies is on the list, involving more than 20 listed companies or subsidiaries

On July 1, the National Health and Health Commission issued《第一批国家重点监控合理用药药品目录(化药/生物制品)》(hereinafter referred to as “《目录》”), and the provinces will form a provincial-level key monitoring and rational drug list on the basis of this catalogue and publish it, focusing on the clinical application of drugs in the catalogue. "God medicine" retreats faster.

According to the incomplete statistics of the Beijing News reporter, the catalogue includes 20 kinds of drugs such as gangliosides and cerebrosides, involving 671 drug approvals. The list of 172 pharmaceutical companies is on the list, including more than 20 listed companies or subsidiaries. According to the data of the drug Rubik's Cube, the total market size of the above varieties is 47.5 billion yuan (based on sales in 2018).

"God medicine" "all-purpose medicine" has already begun to retreat

The national level《目录》released on July 1 includes 20 varieties, including gangliosides, calf serum deproteinized, cinepazide maleate, etc. 12 of them are neuro/vascular protective agents, 3 It is a cell protectant, three are immunomodulators, and there are energy supplements and others.

Previously, the National Health and Health Commission had been expressing these varieties with “auxiliary medications”. However, due to the controversy over the definition of “auxiliary medications” in the industry, companies also opposed this term. The catalogue published this time did not use the term “auxiliary medication”. Although the title has changed, such drugs that have been labeled as "universal medicine" and "medicine medicine" have always been criticized. Under the medical and medical system, such high-priced, high-dose drugs have long occupied medical insurance. The funds, which account for the majority of injections, are TOP30 varieties in the clinical drug market in each province.

In fact, as early as 2015, the nation’s action to retreat “God Medicine” has begun. On February 28, 2015, the General Office of the State Council issued《关于完善公立医院药品集中采购工作的指导意见》, clearly proposing “focus on monitoring and monitoring of auxiliary drugs, drugs used in hospitals, and clear prescription rights for physicians.”

xx2016年4月,国务院办公厅发布《深化医药卫生体制改革2016年重点工作任务》明确指出,公立医院改革试点城市应列出具体清单,对辅助营养等高价药物的不合理使用实施重点监测。从那时起,各地也开始制定限制补充药物使用的政策。

2018年12月14日,国家卫生和健康委员会发出通知,要求各省卫生行政部门组织该地区的二级药品医疗机构报告辅助药品清单,品种数量不得少于20个。这个国家级《目录》是根据该省报告的目录形成的。

目录中列出了七种四环药品种

“新京报”记者从国家食品药品监督管理局的数据库中发现,目录中涉及的20个品种共获得671种药品批准,其中批准最多的是脑蛋白水解物(115份批准),其次是胸腺五肽(100份)批准)。三种小牛血清去蛋白,曲克芦丁脑蛋白水解物和复合辅酶仅由复星医药控制的奥宏药业,四环药业和北京双鹿药业等企业生产。

Kang Enbei,Sihuan Medicine,Shutai Shen等20多家上市公司或其公司都有产品进入目录。药物Rubik's Cube的数据显示,目录中的20个品种共涉及172家公司,总市场规模为475亿元。受影响最大的是四环制药的子公司四环制药。共有7种产品进入目录并占有很大的市场份额;复星医药目录中还有4种产品。

这次发布的目录只是第一批。根据过去发布的辅助药物关键监测目录,受影响的企业远远超过这些目录。光大证券发布的研究报告指出,60多家医药上市公司的产品涉及辅助药品,包括丽珠集团,步昌制药,宏日药业,中恒集团,裕恒药业,赛生药业,雅宝药业,四环医药等。

列表中药物的临床使用与性能有关

文章和原则,并进行处方审查和处方审查;对于药品使用不合理的品种,应及时通知排名,整改,并取消机构的药品目录,确保合理用药。

目录中包含的药物的临床使用将作为医疗机构及其主要负责人的评估内容,并结合医疗机构的验证,评估和绩效评估,评估结果将及时公布。

虽然《目录》仅涉及化学/生物制剂,但国家卫生和健康委员会强调,有必要加强目录以外药物的处方管理,并明确要求医生的处方权限。对于未包含在目录管理中的药物,还需要进行常规临床使用。监测工作,发现使用异常增长,无适应症,过量使用等问题,必须加强预警,找到原因。

此外,国家卫生和健康委员会还为开辟中医药的长期西药“开刀”。要求中医以外的其他类型的医生在中医学习至少一年并通过考试后完成该系统。中医处方。业内人士认为,这将有效遏制滥用被批评的中成药。

新京报记者王卡拉